Dataset Information

Large-Scale Ex Vivo Generation of Human Red Blood Cells from Cord Blood CD34⁺ Cells.

ABSTRACT: The ex vivo generation of human red blood cells on a large scale from hematopoietic stem and progenitor cells has been considered as a potential method to overcome blood supply shortages. Here, we report that functional human erythrocytes can be efficiently produced from cord blood (CB) CD34⁺ cells using a bottle turning device culture system. Safety and efficiency studies were performed in murine and nonhuman primate (NHP) models. With the selected optimized culture conditions, one human CB CD34⁺ cell could be induced ex vivo to produce up to 200 million erythrocytes with a purity of 90.1%?±?6.2% and 50%?±?5.7% (mean?±?SD) for CD235a⁺ cells and enucleated cells, respectively. The yield of erythrocytes from one CB unit (5 million CD34⁺ cells) could be, in theory, equivalent to 500 blood transfusion units in clinical application. Moreover, induced human erythrocytes had normal hemoglobin content and could continue to undergo terminal maturation in the murine xenotransplantation model. In NHP model, xenotransplantation of induced human erythrocytes enhanced hematological recovery and ameliorated the hypoxia situation in the primates with hemorrhagic anemia. These findings suggested that the ex vivo-generated erythrocytes could be an alternative blood source for traditional transfusion products in the clinic. Stem Cells Translational Medicine 2017;6:1698-1709.

SUBMITTER: Zhang Y

PROVIDER: S-EPMC5689780 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Large-Scale Ex Vivo Generation of Human Red Blood Cells from Cord Blood CD34<sup>+</sup> Cells.

Zhang Yu Y Wang Chen C Wang Lan L Shen Bin B Guan Xin X Tian Jing J Ren Zhihua Z Ding Xinxin X Ma Yupo Y Dai Wei W Jiang Yongping Y

Stem cells translational medicine 20170615 8

The ex vivo generation of human red blood cells on a large scale from hematopoietic stem and progenitor cells has been considered as a potential method to overcome blood supply shortages. Here, we report that functional human erythrocytes can be efficiently produced from cord blood (CB) CD34<sup>+</sup> cells using a bottle turning device culture system. Safety and efficiency studies were performed in murine and nonhuman primate (NHP) models. With the selected optimized culture conditions, one h ...[more]

PMID: 28618139

Similar Datasets

Project description:Diabetes can impair wound closure, which can give rise to major clinical problems. Most treatments for wound repair in diabetes remain ineffective. This study aimed to investigate the influence on wound closure of treatments using expanded human cord blood CD34(+) cells (CB-CD34(+) cells), freshly isolated CB-CD34(+) cells and a cytokine cocktail. The test subjects were mice with streptozotocin-induced diabetes. Wounds treated with fresh CB-CD34(+) cells showed more rapid repair than mice given the PBS control. Injection of expanded CB-CD34(+) cells improved wound closure significantly, whereas the injection of the cytokine cocktail alone did not improve wound repair. The results also demonstrated a significant decrease in epithelial gaps and advanced re-epithelialization over the wound bed area after treatment with either expanded CB-CD34(+) cells or freshly isolated cells compared with the control. In addition, treatments with both CB-CD34(+) cells and the cytokine cocktail were shown to promote recruitment of CD31(+)-endothelial cells in the wounds. Both the CB-CD34(+) cell population and the cytokine treatments also enhanced the recruitment of CD68-positive cells in the early stages (day 3) of treatment compared with PBS control, although the degree of this enhancement was found to decline in the later stages (day 9). These results demonstrated that expanded CB-CD34(+) cells or freshly isolated CB-CD34(+) cells could accelerate wound repair by increasing the recruitment of macrophages and capillaries and the reepithelialization over the wound bed area. Our data suggest an effective role in wound closure for both ex vivo expanded CB-CD34(+) cells and freshly isolated cells, and these may serve as therapeutic options for wound treatment for diabetic patients. Wound closure acceleration by expanded CB-CD34(+) cells also breaks the insufficient quantity obstacle of stem cells per unit of cord blood and other stem cell sources, which indicates a broader potential for autologous transplantation.

Dataset Information

Large-Scale Ex Vivo Generation of Human Red Blood Cells from Cord Blood CD34⁺ Cells.

Publications

Large-Scale Ex Vivo Generation of Human Red Blood Cells from Cord Blood CD34<sup>+</sup> Cells.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Large-Scale Ex Vivo Generation of Human Red Blood Cells from Cord Blood CD34+ Cells.

Publications

Large-Scale Ex Vivo Generation of Human Red Blood Cells from Cord Blood CD34<sup>+</sup> Cells.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Large-Scale Ex Vivo Generation of Human Red Blood Cells from Cord Blood CD34⁺ Cells.